Date: April 19th,2021	
Your Name: Shaohua Chen	
Manuscript Title: KCNN4 is a potential prognostic marker and critical factor affecting the immune statu	s of the tumor
microenvironment in kidney renal clear cell carcinoma	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (grant number 81770759) National Key Research and Development Program of China (grant number 2017YFC0908000) Major Project of Guangxi Innovation Driven (grant number AA18118016) Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33)	
		Time frame: past	36 months
2	Grants or contracts from	√_None	

	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	
5	Payment or honoraria for	√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√_None	
	testimony	T None	
	,		
7	Support for attending	√_None	
	meetings and/or travel		
_			
8	Patents planned, issued or	√_None	
	pending		
_	5		
9	Participation on a Data Safety Monitoring Board or	√_None	
Advisory Board			
10		/ Name	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√_None	
12		√_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√_None	
	financial interests		

This study was funded by the National Natural Science Foundation of China (grant number 81770759), the Major Project of Guangxi Innovation Driven (grant number AA18118016), the National Key Research and Development Program of China (grant number 2017YFC0908000) and the Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33).

Please place an "X" next to the following statement to indicate your agreement:

Date: April 19th,2021	
Your Name: Chengbang Wang	
Manuscript Title: KCNN4 is a potential prognostic marker and critical factor affecting the immune status	of the tumor
microenvironment in kidney renal clear cell carcinoma	
Manuscript number (if known):	·

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (grant number 81770759) National Key Research and Development Program of China (grant number 2017YFC0908000) Major Project of Guangxi Innovation Driven (grant number AA18118016) Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33)	
2	Grants or contracts from any entity (if not indicated	Time frame: pastNone	36 months

	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	
5	Payment or honoraria for	√_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	√_None	
	testimony	None	
	,		
7	Support for attending	√_None	
	meetings and/or travel		
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√_None	
	Stock of Stock options	- NOTIC	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		

This study was funded by the National Natural Science Foundation of China (grant number 81770759), the Major Project of Guangxi Innovation Driven (grant number AA18118016), the National Key Research and Development Program of China (grant number 2017YFC0908000) and the Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33).

Please place an "X" next to the following statement to indicate your agreement:

Date: April 19th,2021	
Your Name: Xiaotao Su	
Manuscript Title: KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the turn	no
microenvironment in kidney renal clear cell carcinoma	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (grant number 81770759) National Key Research and Development Program of China (grant number 2017YFC0908000) Major Project of Guangxi Innovation Driven (grant number AA18118016) Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19- 050-22, 19-185-33, 20- 065-33)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	√_None	

	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	
5	Payment or honoraria for	√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	None	
0	testimony	None	
7	Support for attending	√ None	
	meetings and/or travel		
	g ,		
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√_None	
	Safety Monitoring Board or		
10	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	,		
12	Receipt of equipment,	√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		

This study was funded by the National Natural Science Foundation of China (grant number 81770759), the Major Project of Guangxi Innovation Driven (grant number AA18118016), the National Key Research and Development Program of China (grant number 2017YFC0908000) and the Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33).

Please place an "X" next to the following statement to indicate your agreement:

Date: April 19th,2021	
Your Name: Xiaodi Dai	_
Manuscript Title: KCNN4 is a potential prognostic marker and critical factor affecting the immune statu	s of the tumor
microenvironment in kidney renal clear cell carcinoma	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (grant number 81770759) National Key Research and Development Program of China (grant number 2017YFC0908000) Major Project of Guangxi Innovation Driven (grant number AA18118016) Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33)	
2	Grants or contracts from any entity (if not indicated	Time frame: pastNone	36 months

	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	
5	Payment or honoraria for	√_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	√_None	
	testimony	None	
	,		
7	Support for attending	√_None	
	meetings and/or travel		
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√_None	
	Stock of Stock options	- TVOITE	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		

This study was funded by the National Natural Science Foundation of China (grant number 81770759), the Major Project of Guangxi Innovation Driven (grant number AA18118016), the National Key Research and Development Program of China (grant number 2017YFC0908000) and the Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33).

Please place an "X" next to the following statement to indicate your agreement:

Date: April 19th,2021
Your Name: Songheng Li
Manuscript Title: KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the tumo
microenvironment in kidney renal clear cell carcinoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (grant number 81770759) National Key Research and Development Program of China (grant number 2017YFC0908000) Major Project of Guangxi Innovation Driven (grant number AA18118016) Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33)	
2	Grants or contracts from any entity (if not indicated	Time frame: pastNone	36 months

	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	
5	Payment or honoraria for	√_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	√_None	
	testimony	None	
	,		
7	Support for attending	√_None	
	meetings and/or travel		
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√_None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√_None	
	State of State Options		
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		

This study was funded by the National Natural Science Foundation of China (grant number 81770759), the Major Project of Guangxi Innovation Driven (grant number AA18118016), the National Key Research and Development Program of China (grant number 2017YFC0908000) and the Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33).

Please place an "X" next to the following statement to indicate your agreement:

Date: April 19th,2021	
Your Name: Zengnan Mo	
Manuscript Title: KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the	tumo
microenvironment in kidney renal clear cell carcinoma	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China (grant number 81770759) National Key Research and Development Program of China (grant number 2017YFC0908000) Major Project of Guangxi Innovation Driven (grant number AA18118016) Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33)	
2	Grants or contracts from any entity (if not indicated	Time frame: pastNone	36 months

	in item #1 above).		
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	
5	Payment or honoraria for	√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	None	
"	testimony	None	
7	Support for attending	√ None	
	meetings and/or travel		
	g ,		
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√_None	
	Safety Monitoring Board or		
10	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	,		
12	Receipt of equipment,	√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		

This study was funded by the National Natural Science Foundation of China (grant number 81770759), the Major Project of Guangxi Innovation Driven (grant number AA18118016), the National Key Research and Development Program of China (grant number 2017YFC0908000) and the Guangxi key Laboratory for Genomic and Personalized Medicine (grant number 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33).

Please place an "X" next to the following statement to indicate your agreement: